Secreted Phospholipase A2 (sPLA2) has been implicated in many diseases because of its role in inflammation and host
defense. sPLA2 is found in many mammalian tissues as well as insect and snake venom. sPLA2 catalyses
the release of arachidonic acid and is involved in the production of prostaglandins for inflammation. sPLA2
is present in connection with multiple diseases including rheumatoid arthritis, sepsis, psoriasis, pancreatitis, cancer, Crohn's
disease, and multiple sclerosis.
There has been a great deal of research done by both academia and pharmaceutical companies to find chemical inhibitors to
sPLA2. However, there has also been research on more natural methods for inhibiting sPLA2 . Analysis has shown that
treatment with supplements of Cytidine 5-diphospho-choline (CDP-choline) can limit the ability of sPLA2 to promote
inflammation. Studies of CDP-choline of over 11,000 volunteers and patients have shown beneficial effects for many different
conditions including cerebral ischemia, traumatic brain injury, hypoxia, Alzheimer's, Parkinson's memory disorders, and
glaucoma. CDP-choline is composed of cytidine and choline linked by a diphosphate bridge.
CDP-choline is an essential intermediate of the major brain phospholipid, phosphatidylcholine. Increasing amounts of CDP-
choline resultsin the decreased activation of sPLA2, which then results in the decreased production of arachidonic acid and